Drug Profile
ACH 2928
Alternative Names: ACH-2928Latest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 31 Dec 2012 Discontinued - Phase-I for Hepatitis C in USA (PO)
- 05 Dec 2011 Interim efficacy and adverse events data from a phase Ia/Ib trial in Hepatitis C (patients and volunteers) released by Achillion Pharmaceuticals